Evidence labels explain what kind of source is being read.
Dictionary / Evidence method
RCT
Randomized controlled trial; one study-design term used in evidence summaries.
Evidence methodterm category
0related public pages
editorial navigationdefinition status
draftreview status
73exact evidence rows
43exact source links
0nearby evidence rows
0nearby source links
1do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
RCT explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
43 direct sources linked to approved workbench claims. PubMed 37796540
0 nearby evidence rows and 0 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
RCT is used in this encyclopedia as a evidence method term. Randomized controlled trial; one study-design term used in evidence summaries.
Evidence-method terms describe how a source should be read. They help separate human trials, observational work, preclinical work, mechanistic studies, and explicit evidence gaps.
Also searched as: controlled trial, randomised controlled trial, randomized controlled trial.
Do not confuse with:
Evidence Guardrail
How to read it without overreaching
Use this term to classify the kind of evidence, not to inflate it. A stronger-sounding label still needs source details, study context, outcome measures, and limits.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 37796540
Distinct source records under those exact rows. PubMed 37796540
Source-backed public pages where this vocabulary is likely useful.
Evidence rows available on those related public pages.
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 37796540
- Open related pages.Use nearby pages for broader source-backed context.
- Keep the boundary.A method label describes evidence type; it does not make the evidence stronger.
Exact Evidence Rows
Approved source-backed rows linked to this term
73 exact rows
No matching evidence rows.
Evidence Group
Preliminary Human
53 exact rows / 29 sources
Evidence row 2 / uses term
CBN decreases Nighttime awakenings.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 3 / uses term
CBN no detected effect on sleep onset latency, wake after sleep onset, or daytime fatigue.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 4 / uses term
CBN decreases Overall sleep disturbance.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 5 / uses term
CBN no detected effect on Side effect frequency.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 6 / uses term
CBN no detected effect on Wake after sleep onset.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 7 / uses term
CBN decreases Sleep onset latency.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 8 / uses term
CBN increases Subjective sleep quality.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 9 / uses term
CBN increases NREM-2 sleep.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 14 / uses term
CBN decreases Overall sleep disturbance.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 15 / uses term
CBN associated with Adverse events.
preliminary human / low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 16 / uses term
CBN no detected effect on Sleep onset latency.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 17 / uses term
CBN no detected effect on Wake after sleep onset.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 18 / uses term
CBN no detected effect on Daytime fatigue.
preliminary human / moderate confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 28 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. PubMed 38797087
Claim or source metadata contains an explicit term marker.
Evidence row 29 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial. PubMed 35617670
Claim or source metadata contains an explicit term marker.
Evidence row 57 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PubMed 38174873
Claim or source metadata contains an explicit term marker.
Evidence row 59 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer: A Randomized Clinical Trial. PubMed 39680411
Claim or source metadata contains an explicit term marker.
Evidence row 60 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial. PubMed 39505200
Claim or source metadata contains an explicit term marker.
Evidence row 62 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 108 / uses term
CBN studied for Sleep.
preliminary human / very_low confidence.
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PubMed 39980821
Claim or source metadata contains an explicit term marker.
Evidence row 120 / uses term
CBDV studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. PubMed 34210360
Claim or source metadata contains an explicit term marker.
Evidence row 149 / uses term
CBN studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 159 / uses term
CBG studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Claim or source metadata contains an explicit term marker.
Evidence row 169 / uses term
CBC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 233 / uses term
THC studied for Cannabinoids and nausea/vomiting research outcomes.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 366 / uses term
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
preliminary human / very_low confidence.
Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. PubMed 40622698
Claim or source metadata contains an explicit term marker.
Evidence row 382 / uses term
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. PubMed 33346789
Claim or source metadata contains an explicit term marker.
Evidence row 395 / uses term
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial. PubMed 37630995
Claim or source metadata contains an explicit term marker.
Evidence row 396 / uses term
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial. PubMed 42256679
Claim or source metadata contains an explicit term marker.
Evidence row 403 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. PubMed 38174873
Claim or source metadata contains an explicit term marker.
Evidence row 404 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PubMed 39980821
Claim or source metadata contains an explicit term marker.
Evidence row 405 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. PubMed 36539991
Claim or source metadata contains an explicit term marker.
Evidence row 406 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. PubMed 39167421
Claim or source metadata contains an explicit term marker.
Evidence row 407 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial. PubMed 39153080
Claim or source metadata contains an explicit term marker.
Evidence row 409 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PubMed 40631525
Claim or source metadata contains an explicit term marker.
Evidence row 414 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial. PubMed 38758300
Claim or source metadata contains an explicit term marker.
Evidence row 417 / uses term
CBD studied for Seizure and neurodevelopmental outcomes.
preliminary human / very_low confidence.
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. PubMed 29395273
Claim or source metadata contains an explicit term marker.
Evidence row 432 / uses term
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. PubMed 33118602
Claim or source metadata contains an explicit term marker.
Evidence row 433 / uses term
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study. PubMed 42261989
Claim or source metadata contains an explicit term marker.
Evidence row 462 / uses term
THC studied for Cognition and memory.
preliminary human / very_low confidence.
Δ9-Tetrahydrocannabinol (THC) impairs visual working memory performance: a randomized crossover trial. PubMed 32386395
Claim or source metadata contains an explicit term marker.
Evidence row 474 / uses term
THC studied for Pain-related outcomes.
preliminary human / very_low confidence.
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. PubMed 33118602
Claim or source metadata contains an explicit term marker.
Evidence row 482 / uses term
THC studied for Nausea and vomiting.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 492 / uses term
THC studied for Appetite and metabolic outcomes.
preliminary human / very_low confidence.
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. PubMed 16849753
Claim or source metadata contains an explicit term marker.
Evidence row 499 / uses term
THC studied for Sleep.
preliminary human / very_low confidence.
Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. PubMed 36539991
Claim or source metadata contains an explicit term marker.
Evidence row 500 / uses term
THC studied for Sleep.
preliminary human / very_low confidence.
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PubMed 40631525
Claim or source metadata contains an explicit term marker.
Evidence row 503 / uses term
THC studied for Sleep.
preliminary human / very_low confidence.
Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. PubMed 32430450
Claim or source metadata contains an explicit term marker.
Evidence row 508 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality PubMed 37796540
Claim or source metadata contains an explicit term marker.
Evidence row 509 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 510 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double-Blind Placebo-Controlled Crossover Pilot Trial. PubMed 39980821
Claim or source metadata contains an explicit term marker.
Evidence row 512 / uses term
CBN studied for safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 544 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). PubMed 37947792
Claim or source metadata contains an explicit term marker.
Evidence row 641 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preliminary human / very_low confidence.
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. PubMed 37162192
Claim or source metadata contains an explicit term marker.
Evidence row 745 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preliminary human / very_low confidence.
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. PubMed 37721990
Claim or source metadata contains an explicit term marker.
Evidence Group
Insufficient
12 exact rows / 9 sources
Evidence row 20 / uses term
CBN studied for Sleep.
insufficient / very_low confidence.
Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder ('CUPID' study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. PubMed 37612115
Claim or source metadata contains an explicit term marker.
Evidence row 98 / uses term
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Claim or source metadata contains an explicit term marker.
Evidence row 196 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 217 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Claim or source metadata contains an explicit term marker.
Evidence row 320 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Claim or source metadata contains an explicit term marker.
Evidence row 397 / uses term
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials. PubMed 33561282
Claim or source metadata contains an explicit term marker.
Evidence row 400 / uses term
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials. PubMed 39445260
Claim or source metadata contains an explicit term marker.
Evidence row 410 / uses term
CBD studied for Sleep.
insufficient / very_low confidence.
Effectiveness of cannabinoids on subjective sleep quality in people with and without insomnia or poor sleep: A systematic review and meta-analysis of randomised studies. PubMed 40929927
Claim or source metadata contains an explicit term marker.
Evidence row 423 / uses term
CBD studied for Seizure and neurodevelopmental outcomes.
insufficient / very_low confidence.
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. PubMed 37695433
Claim or source metadata contains an explicit term marker.
Evidence row 430 / uses term
CBD studied for Pain-related outcomes.
insufficient / very_low confidence.
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. PubMed 37648266
Claim or source metadata contains an explicit term marker.
Evidence row 574 / uses term
CBG modulates receptor, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. PubMed 39003387
Claim or source metadata contains an explicit term marker.
Evidence row 1105 / uses term
OEA studied for OEA biology, receptor pharmacology, feeding, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. PubMed 31132422
Claim or source metadata contains an explicit term marker.
Evidence Group
Mechanistic or Pharmacological
8 exact rows / 6 sources
Evidence row 47 / uses term
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
mechanistic or pharmacological / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 77 / uses term
THCV studied for Appetite and metabolic outcomes.
mechanistic or pharmacological / very_low confidence.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PubMed 27573936
Claim or source metadata contains an explicit term marker.
Evidence row 322 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Cannabinoid treatment for autism: a proof-of-concept randomized trial. PubMed 33536055
Claim or source metadata contains an explicit term marker.
Evidence row 422 / uses term
CBD studied for Seizure and neurodevelopmental outcomes.
mechanistic or pharmacological / very_low confidence.
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. PubMed 29540584
Claim or source metadata contains an explicit term marker.
Evidence row 431 / uses term
CBD studied for Pain-related outcomes.
mechanistic or pharmacological / very_low confidence.
An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. PubMed 30585986
Claim or source metadata contains an explicit term marker.
Evidence row 738 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. PubMed 27573936
Claim or source metadata contains an explicit term marker.
Evidence row 751 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PubMed 26577065
Claim or source metadata contains an explicit term marker.
Evidence row 791 / uses term
THCV studied for neurobehavioral, cognition, mood, reward, or THC-interaction outcomes.
mechanistic or pharmacological / very_low confidence.
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. PubMed 26577065
Claim or source metadata contains an explicit term marker.
Source-Backed Connections
Related pages in the current encyclopedia
No source-backed public page is linked to this term in the current launch set yet. Start with the evidence method, then add sources as the term page matures.
Nearby Terms